Clinical trial · Interventional
Exploratory Study of Intermittent Hypoxia Intervention on Colorectal Cancer
Exploratory Study of the Impact of Intermittent Hypoxia Intervention on Patients With Colorectal Cancer
NCT06584318CI-TRIAL-00090224recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the safety and efficacy of intermittent hypoxia intervention on patients with colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intermittent hypoxia intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patients
- description
- Participants will receive 14 times intermittent hypoxia (oxygen concentration: 13%) intervention before the surgery.
- interventionNames
- Other: Intermittent hypoxia intervention
Primary outcomes (1)
- measure
- Incidence of adverse reactions
- timeFrame
- During the 7-day treatment
- description
- Adverse reactions included headache, vomiting, diarrhea, fatigue, dizziness and insomnia.
Secondary outcomes (5)
- measure
- Tumor Markers
- timeFrame
- The day before the 7-day treatment ; the day of surgery (1-7days post the treatment)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with colorectal cancer between ages of 18 and 65 years. * Colorectal cancer stage Ⅰ,Ⅱ. * Subjects or their legally authorized representative can provide informed consent. Exclusion Criteria: * History of cardiovascular, cerebrovascular, dermatological, and hematological diseases. * History of pulmonary, hepatic, kidney, dermatologic and hematologic diseases. * History of pregnancy, hypertension, diabetes mellitus, obesity, sleep apnea and neurological disorders. * History of substance abuse. * Participating in other drug or medical device studies. * History of organ transplantation, including allogeneic stem cell and immune cell transplantation. * Recent severe infection within 4 weeks. * Received cancer treatment, including chemotherapy and radiotherapy, within 4 weeks. * Underwent major surgery within 28 days.
References
Publications (0)
Data not yet available
No reference posted for this study.